# OnCo record belinostat (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/belinostat/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "belinostat" ;
  schema:name "Belinostat"@en ;
  schema:description "Belinostat is an HDAC inhibitor for relapsed peripheral T-cell lymphoma; about a quarter of patients respond, and it can be used in patients with low platelets."@en ;
  schema:url <https://onco.cc/drugs/belinostat/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Belinostat> ;
  owl:sameAs <http://www.wikidata.org/entity/Q4882925> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=belinostat> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Pan-HDAC inhibitor (hydroxamate)" ;
  schema:alternateName "Beleodaq" ;
  onco:approval "US 2014: Relapsed/refractory peripheral T-cell lymphoma" ;
  onco:acceleratedApproval "US 2014-07-03: Treatment of relapsed or refractory peripheral T-Cell Lymphoma (PTCL)" ;
  onco:cancers <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:companies <https://onco.cc/companies/acrotech-biopharma/>, <https://onco.cc/companies/spectrum-pharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/nct06072131/> .